Drug Side Effects

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test

By

Hypersensitivity reactions are a classic and serious side effect of cetuximab.

Acupuncture improves quality of life for breast cancer patients taking aromatase inhibitors (AIs)

By

Electroacupuncture (EA) produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for patients with early stage breast cancer experiencing joint pain related to the use of aromatase inhibitors to treat breast cancer.

Promising medication counteracts opioid-caused constipation

By

A newly developed opioid antagonist may offer relief from opioid-caused constipation.

ESHRE: Low evidence of fertility drug and cancer link

ESHRE: Low evidence of fertility drug and cancer link

Use of fertility drugs doesn't appear to increase a woman's long-term risk of breast, ovarian, and uterine cancers, new research indicates, but researchers still urge long-term monitoring.

Can docetaxel cause intoxication in cancer patients?

Can docetaxel cause intoxication in cancer patients?

The FDA issued an alert last Friday that some patients have reported feeling intoxicated after receiving their infusions of the chemotherapeutic drug, docetaxel.

Benefits of trastuzumab outweigh risk of harm for advanced breast cancer

By

In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug trastuzumab is associated with prolonged survival but also increases the risk of developing heart problems

Second opinion on lung cancer changes diagnosis from advanced to early and curable

By

A woman was diagnosed with advanced, incurable lung cancer that, in fact, was early stage, curable lung cancer with additional lung lesions due to a rare antibiotic side effect.

Impact of fertility drugs on breast cancer risk examined

Impact of fertility drugs on breast cancer risk examined

Women with ever use of clomiphene have no increased breast cancer risk, although women undergoing multiple clomiphene cycles have an increased risk of invasive breast cancer.

Managing peripheral neuropathy related to vincristine

Managing peripheral neuropathy related to vincristine

By

Has any medicine or supplement been shown to help lessen the severity of vincristine-related peripheral neuropathy?

How to manage myoclonus in patients on high-dose opioids

How to manage myoclonus in patients on high-dose opioids

By

How should myoclonus be managed in patients taking high-dose opioids?

High cholesterol fuels breast cancer growth and spread

High cholesterol fuels breast cancer growth and spread

By

A by-product of cholesterol functions like the hormone estrogen to fuel the growth and spread of the most common types of breast cancers, according to researchers.

Secondary cancers: When treatment ­increases the risk of disease

Secondary cancers: When treatment ­increases the risk of disease

By

Which cancer treatments can cause other cancers later in life?

Kidney cancer drugs demonstrate similar efficacy

Kidney cancer drugs demonstrate similar efficacy

Although pazopanib and sunitinib are similarly effective in patients with metastatic renal-cell cancer, pazopanib is associated with better safety and quality of life, according to a study.

Neurotoxicity from 
oxaliplatin

Neurotoxicity from 
oxaliplatin

By

What are some of the potential autonomic issues related to acute neurotoxicity from oxaliplatin?

Proper use of denosumab for skeletal conditions

Proper use of denosumab for skeletal conditions

By

What should nurses be aware of when administering denosumab?

One-quarter of patients do not complete recommended breast cancer treatment

By

One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the 5-year course, according to a new study.

Managing chemotherapy side effects: Tumor lysis syndrome

Managing chemotherapy side effects: Tumor lysis syndrome

Patients undergoing chemotherapy for hematologic cancers are at risk for this complication. The review can help you learn how to assess their risk.

Ibrutinib may be a breakthrough for treatment of a rare lymphoma

Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.

Pomalidomide extends survival in multiple myeloma

A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.

Zytiga approved for metastatic prostate cancer

The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.

Study drug makes marrow transplant possible in relapsed leukemia

The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.

Ibrutinib appears safe, effective against chronic lymphocytic leukemia

Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.

Anticancer agent reduces complications after stem-cell transplant

Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.

FDA pulls 32-mg IV ondansetron dose from market

The 32-mg, single IV dose of the anti-nausea drug Zofran (ondansetron) will no longer be sold due to the potential for serious cardiac risks.

Regorafenib prolongs survival in face of GI cancers

Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.

Trastuzumab raises heart risk in older women with breast cancer

Heart failure is relatively common in older women undergoing breast cancer treatment, but trastuzumab therapy appears to raise the risk even more.

Denosumab extended survival in lung cancer with bone metastases

By

Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.

Everolimus shrinks astrocytoma brain tumors

The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.

Withdrawn leukemia drug has good results in UK study

Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.

Drug combo shows promise in triple-negative breast cancer

Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs